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Summary Paclitaxel has demonstrated broad clinical activity in a variety of malignancies both alone and in
combination with other chemotherapeutic agents. The in vitro cytotoxicity of a 2 h exposure to paclitaxel,
hydroperoxy-ifosfamide and etoposide alone, in combination and in sequence, was evaluated against
established cisplatin-sensitive and cisplatin-refractory human ovarian carcinoma cell lines using isobologram
analysis. The combinations ofeither paclitaxel-hydroperoxy-ifosfamide or paclitaxel-etoposide were found to
be additive or synergistic when the drugs were given simultaneously or when paclitaxel was given 24 h before
hydroperoxy-ifosfamide or etoposide respectively. However, when etoposide or hydroperoxy-ifosfamide were
given before paclitaxel, antagonistic interactions were observed. With regard to etoposide this antagonism was
evident for up to 24 h. In agreement with our data with the schedule-dependent interactions of paclitaxel and
cisplatin in human gastric and ovarian carcinoma cell lines, these data demonstrate that the interactions of
paclitaxel, etoposide and hydroperoxy-ifosfamide are also highly schedule dependent and applications of
etoposide or ifosfamide before pacitaxel may result in pronounced antagonism. These findings could have
implications for the design of further clinical protocols.
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Despite the improvement in therapy of ovarian cancer
achieved by the introduction of platinum compounds since
1980, a major problem remains: the emergence of resistant
tumour cell populations resulting in progressive ovarian
cancer in the majority of patients presenting with advanced
disease (Ozols, 1985).
Paclitaxel, an antimicrotubule agent, has shown clear
activity as salvage therapy in epithelial ovarian carcinoma.
Most important, it demonstrates activity in tumours that
have displayed resistance to platinum compounds, a situation
in which other salvage therapies have very limited activity
(Thigpen et al., 1994). The role of paclitaxel combined with
cisplatin in the initial treatment of advanced disease is
currently being explored (McGuire et al., 1993). With regard
to the combination of paclitaxel and cisplatin it has become
clear that the cytotoxic activity of the combination strongly
depends on the sequence of administration (Rowinsky et al.,
1991; Jekunen et al., 1994). Hydroperoxy-ifosfamide as well
as etoposide have shown single-agent activity in the second-
line treatment of ovarian cancer with response rates of
approximately 20%. There is clearly a need to develop new
salvage strategies and combination protocols in the treatment
of ovarian cancer.
In order to further elucidate this issue, we investigated the
interactions of either paclitaxel and hydroperoxy-ifosfamide
and of paclitaxel and etoposide in vitro in cisplatin-sensitive
and cisplatin-refractory human ovarian cancer cell lines.
Materials and Methods
Drugs and chemicals
Paclitaxel, etoposide and sulphorhodamin B reagent were
supplied by Sigma (Deisenhofen, Germany). Hydroperoxy-
ifosfamide was supplied by ASTA (Bielefeld, Germany).
RPMI-1640 medium and Dulbecco's modified Eagle medium
(DMEM) were obtained from Gibco/Life Technology
(Eggenstein, Germany). The [3H]paclitaxel (sp. act. 19
Ci mmol-') was from Peasel-Lorei (Frankfurt, Germany)
and found to be 99.9% pure by high-pressure liquid
chromatography. All drug solutions were prepared freshly
before use.
Cell lines and culture techniques
The human ovarian carcinoma cell line A2780 (WT for 'wild
type') was established from a non-pretreated patient with
ovarian carcinoma, and the cisplatin-resistant variant A2780
CP2 was obtained from R Ozols and T Hamilton (Fox Chase
Cancer Center, Philadelphia, PA, USA) (Rogan et al., 1984).
A2780 CP2 cells are about 15-fold resistant to cisplatin
(Masuda et al., 1988; Hamilton et al., 1985). The human
ovarian adenocarcinoma cell lines TR 170 and the cisplatin-
resistant subline TR 170/731 were obtained from BT Hill
(Pierre Fabre Research Center, Paris, France). The cisplatin-
resistant line TR 170/731 was generated by intermittent
exposure to cisplatin with a 10-fold resistance. The cell lines
were maintained in RPMI1640 containing L-glutamine, 10%
heat-inactivated fetal calf serum and 25% DMEM. All cell
lines were kept in an atmosphere of 5% carbon dioxide in air
at 37°C.
Cytotoxicity assay
The cytotoxicity of either paclitaxel, etoposide and hydro-
peroxy-ifosfamide was assessed by sulphorhodamin B assay
(Skehan et al., 1990). Cells in exponential growth were
washed with phosphate-buffered saline (PBS), trypsinised
with 0.25% trypsin/EDTA for 2 min at 37°C, counted and
seeded as a single-cell suspension at a density of 1000 cells
per well (A2780; A2780 CP2) or 5000 cells per well (TR 170;
TR 170/731) respectively in 96-well microtitre plates (Falcon,
Heidelberg, Germany). Cells were allowed to attach over-
night.
After 24 h or 48 h, 100 MuI of medium containing different
concentrations of either paclitaxel, etoposide or ifosfamide
were added for 2 h. The drug-containing medium was
aspirated from the plates and fresh medium was added.
Control dishes without paclitaxel, ifosfamide or etoposide
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February 1996were treated identically. After a total incubation time of
120 h, cells were fixed with 50 pl of 50% trichloroacetic acid
(TCA) for at least 1 h at 4°C, washed three times with PBS
and stained as originally described. Eight wells were used for
each drug concentration and all experiments were performed
in triplicate. The drug concentration that inhibited cell
growth by 50% (IC50) was obtained from semilogarithmic
dose-response plots.
The standard isobologram methodology (50% isodose)
was used to determine the interaction of paclitaxel and
hydroperoxy-ifosfamide or etoposide respectively. The
schedule-dependent interactions of the drug combinations
were classified as synergistic, additive or antagonistic as
described by Berenbaum (1989). In brief, dose-response
curves should be determined for each agent alone, and with
two agents in combination at a fixed ratio equivalent to the
ratio of their IC50 values. The nature of the interaction
between the drugs could then be assessed by median effect
computer analysis of the dose-response curves in order to
calculate the combination index at the level of 50% cell kill.
Values of <1 indicate synergy, a value of 1 indicates
additivity and values >1 indicate antagonism. With the
mathematical basis ofthe combination index by median effect
analysis we are able to analyse the isobols graphically.
Berenbaum determined an upward concavity as synergistic, a
downward concavity as antagonistic (see Figure 1). Each
point in the figure presented represents the mean of three
separate experiments.
[3H]Paclitaxel uptake and retention
Exponentially growing cells of the cell line A2780 CP2 were
seeded in plastic flasks and incubated either with 50% of the
IC50 for etoposide or drug-free medium. Twenty-four hours
later cells were trypsinised, washed twice with PBS and
counted. The [3H]paclitaxel uptake was determined by
exposing 106 cells for 2 h to 50 nM (0.95 1iCi) [3H]paclitaxel
and 150 nm unlabelled paclitaxel (200 nm final concentration)
at 37°C. The [3H]paclitaxel uptake was measured after 5, 10,
20, 30, 60 and 120 min. For the assessment of radioactivity,
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cells were centrifuged at 2000 U min-1, washed three times
with ice-cold PBS and lysed with 1 N sodium hydroxide for
24 h. The lysates were collected and counted in a liquid
scintillation counter. Results are expressed as pmol paclitaxel
(total concentration) 10-6 cells. For the measurement of
[3H]paclitaxel retention, the cells were centrifuged, washed
with ice-cold PBS and resuspended in L-15 medium at 37°C.
Samples were taken after 5, 10, 20, 30, 60 and 120 min and
processed as described above. All experiments were
performed in triplicate.
DNA flow cytometry
To assess the changes in the cell cycle distribution, flow
cytometry analysis was performed 24 h, 48 h and 72 h after
exposure to etoposide in the cisplatin-resistant ovarian cancer
cell line A2780 CP2. Cells were incubated in a DNA staining
solution containing propidium iodide (50 ig ml-') and
RNAase (Type 111-A, bovine pancreas, 4 KU ml-1) and
kept cold and dark for at least 30 min until flow cytometry
analysis was carried out (Krishan, 1975). Cells were analysed
in a Coulter flow cytometer equipped with an argon laser
(488 nm) (Coulter Electronics, Hialeah, FL, USA), and data
were registered and stored in list mode. Debris and damaged
cells were excluded by gating on a forward and side scatter
dot plot or on a DNA histogram. Fluorescence was recorded
Table I IC50 values for cisplatin, paclitaxel, hydroperoxy-ifosfa-
mide (HPI) and etoposide (2h exposure)
IC50 (gM) (±s.d.)
Cell line Cisplatin Paclitaxel HPI Etoposide
A2780 4.8 (0.2) 0.08 (0.002) 5.5 (0.23) 0.9 (0.01)
A2780 CP2 51.0 (1.2) 0.08 (0.001) 27.5 (0.9) 3.0 (0.1)
TR 170 35.0 (1.2) 0.30 (0.01) 30.0 (1.1) 8.3 (0.6)
TR 170/731 89.5 (2.3) 0.30 (0.03) 33.2 (1.3) 8.5 (0.5)
The results are presented as the mean values from threeindependent
experiments.
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Figure 1 Isobologram analysis (50% isodose) of paclitaxel, hydroperoxy-ifosfamide and etoposide in cell lines A2780WT,
A2780CP2, TR 170, TR 170/731. (a, b) Simultaneous application of the drugs. (c) Paclitaxel 24h before hydroperoxy-ifosfamide. (d)
Paclitaxel- 24h before etoposide. (e) Hydroperoxy-ifosfamide 24h before paclitaxel. (f) Etoposide 24h before paclitaxel. *,
A2780WT; 0, A2780CP2; A, TR 170; A, TR 170/731.
0)
E
4-
0-
I
0)
a
0
I-
0.
Q)
u
0 w -0
UJ4
ISchedule-dependent interactions of paclitaxel, etoposide and ifosfamide
U Klaassen et al
100 in the FL3 channel (635 nm) using linear amplification. Data
obtained were evaluated with the multicycle software
(Phoenix Flow Systems, San Diego, CA, USA).
Statistical analysis
The differences between the mean values were analysed for
significance using the unpaired two-tailed Student's t-test for
independent samples; P-values <0.05 were considered to be
statistically significant.
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Results
The ICso values for a 2 h exposure to cisplatin, paclitaxel,
hydroperoxy-ifosfamide and etoposide for the cell lines
A2780, A2780 CP2, TR 170 and TR 170/731 are given in
Table I. The two wild-type lines showed a considerable
difference in sensitivity to cisplatin. Furthermore the
cisplatin-resistant line A2780 CP2 displayed cross-resistance
to ifosfamide and etoposide whereas no such cross-resistance
was observed in TR 170/731.
The isobologram analysis of schedule-dependent interac-
tions between paclitaxel and hydroperoxy-ifosfamide as well
as between paclitaxel and etoposide each in the cell lines
A2780, A2780 CP2, TR 170 and TR 170/731 are displayed in
Figure 1. The combinations of either paclitaxel-hydroper-
oxy-ifosfamide or paclitaxel -etoposide were found to be
additive or synergistic when the drugs were given simulta-
neously or when paclitaxel was given 24 h before hydro-
peroxy-ifosfamide or etoposide respectively. However, when
etoposide or hydroperoxy-ifosfamide were given before
paclitaxel, antagonistic interactions were observed. A
summary of the observed interactions is given in Table II.
In order to assess the extent and the duration of the
protection against paclitaxel cytotoxicity induced by pretreat-
ment with etoposide, A2780 CP2 cells were exposed to a fixed
concentration of etoposide (50% IC50) followed by paclitaxel
for 2 h either 24 h, 48 h or 72 h later. The antagonism of the
sequence etoposide followed by paclitaxel was time
dependent. Pretreatment with etoposide significantly reduced
the activity of paclitaxel for up to 24 h. However, no
reduction of paclitaxel cytotoxicity was seen when the drugs
were given 48 h or 72 h apart (Figure 2).
As etoposide is known to influence progression through
the cell cycle and paclitaxel is a drug with preferential activity
against cells in G2/M phase, we assessed the changes in cell
cycle distribution after exposure to etoposide. The results are
shown in Figure 3. Compared with non-treated cells, a
gradual increase in cells with S-phase and a corresponding
decrease of cells with either G1 or G2/M DNA content was
seen, indicating a temporal transition block at the S/G2
boundary. However, these changes in cell cycle distribution
were discrete and do not offer a sufficient explanation for the
marked antagonism between etoposide and paclitaxel.
To further explain the marked schedule-dependent
antagonism between etoposide and paclitaxel, the effect of
etoposide on the cellular accumulation and retention of 3H-
labelled paclitaxel was measured. No significant differences in
paclitaxel uptake could be detected between cells that were
0
0 100 50
Per cent IC50 Paclitaxel
Figure 2 Cytotoxicity assay of the sequence etoposide followed
by paclitaxel in the cisplatin-resistant cell line A2780 CP2. Cells
were exposed to a fixed concentration of etoposide for 2h (50%
IC50), washed and exposed to paclitaxel either 24h (0), 48h (A)
or 72h (0) and non-pretreated cells (A).
pretreated with etoposide and the untreated cells. Further-
more the peak concentrations ofpaclitaxel at the end of a 2 h
loading period were also not changed. However cells
pretreated with etoposide retained significantly less drug
when incubated in drug-free medium than in non-pretreated
cells (Figure 4).
Discussion
Many groups, including our own, have demonstrated
schedule-dependent interactions between paclitaxel and
cisplatin in human ovarian and gastric cancer cell lines in
vitro and in vivo (Vanhoefer et al., 1995; Jekunen et al., 1994).
The present study demonstrates a marked schedule-
dependent antagonism between paclitaxel and hydroperoxy-
ifosfamide and between paclitaxel and etoposide in cisplatin-
sensitive and cisplatin-refractory human ovarian carcinoma
cell lines. This antagonism was seen for all sequences when
either hydroperoxy-ifosfamide or etoposide were given before
paclitaxel. In contrast, when cells were exposed to paclitaxel
before either hydroperoxy-ifosfamide or etoposide or when a
simultaneous application ofpaclitaxel with one or both drugs
was performed additive or synergistic interactions were seen.
However, unlike cisplatin for which we could demonstrate a
reduction in the activity of paclitaxel up to 72 h after
exposure to cisplatin, the antagonism between etoposide and
paclitaxel could only be demonstrated for 24 h and cells
regained full sensitivity to paclitaxel after 48 h.
As paclitaxel predominantly acts on cells in late G2/M
phase, the cell cycle distributions after exposure to etoposide
were assessed. More cells were observed to be in late S-phase
and G2/M phase 24 h after exposure to etoposide than in the
control samples, indicating that a block of the cell cycle
traverse is most likely not responsible for the observed
antagonism.
Table II Summary of the observed interactions of paclitaxel, hydroperoxy-ifosfamide (HPI) and etoposide
in the human ovarian carcinoma cell lines A2780, A2780 CP2, TR 170 and TR 170/731
A2780 A2780 CP2 TR 170 TR701/731
Paclitaxel/HPI Additive Additive Synergistic Synergistic
Pacitaxel-.HPI Additive Synergistic Additive Synergistic
HPI -.Paclitaxel Antagonistic Antagonistic Additive Antagonistic
Paclitaxel/Etoposide Synergistic Additive Synergistic Synergistic
Paclitaxel -*Etoposide Additive Additive Synergistic Synergistic
Etoposide -*Paclitaxel Antagonistic Antagonistic Antagonistic Antagonistic
All experiments were performed in triplicate.Schedule-dependent interactions of pacHtaxel, etoposide and ifosfamide
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Figure 3 Cell cycle distribution in the cell line A2780 CP2 24h
(0), 48h (0), 72h (A) after 2h exposure to drug-free medium
(a) and etoposide (50% of IC50) (b).
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The biochemical basis for these schedule-dependent
interactions between paclitaxel and either cisplatin, etoposide
or hydroperoxy-ifosfamide have not been fully elucidated. It
has been demonstrated that pretreatment with cisplatin
reduces the retention of paclitaxel inside the cell. This might
be due to alterations of the tubulin binding site, which will
result in reduced activity of paclitaxel. Additionally, it could
be demonstrated that a profound depletion of cellular
glutathione pools will also reduce the efficacy of paclitaxel
in vitro (Vanhoefer et al., 1995). Furthermore, clinical data
have shown a reduced total body clearance of paclitaxel in
patients who have been pretreated with cisplatin (Rowinsky
et al., 1991). Therefore a detailed investigation of the
influence of drug scheduling on the cytotoxic efficacy of
combinations containing paclitaxel might lead to a more
rational design of clinical protocols.
In the present study etoposide had no effect on the cellular
uptake of 3H-labelled paclitaxel. However, as also demon-
strated for cisplatin a significantly increased retention of
paclitaxel in non-pretreated cells was seen compared with
cells that have been exposed to etoposide. Further studies will
have to clarify whether the reduced cellular retention of
paclitaxel is due to changes in the affinity of tubulin binding
sites for paclitaxel, which could be one explanation for the
schedule-dependent interactions.
These in vitro data suggest that clinical protocols using the
Figure 4 Effect of etoposide on the cellular accumulation of
[3H]paclitaxel in the cell line A2780 CP2. (a) Uptake of
[3H]paclitaxel in the cell line A2780 CP2. Cells were preincubated
for 2h with 50% of the IC50 of etoposide and exposed 24h later
to 50 nM [3H]paclitaxel 150 Mn paclitaxel (0, pretreated with
etoposide; 0, non-pretreated). (b) Retention of [ H]paclitaxel in
the cell line A2780 CP2. Cells were washed and resuspended in
drug-free medium (0, pretreated with etoposide; 0, non-
pretreated).
sequence of either etoposide or ifosfamide followed by
paclitaxel could have reduced therapeutic efficacy. We have
started a phase I study with paclitaxel given on day 1
followed by ifosfamide given on days 2-5 in cisplatin-
pretreated ovarian cancer patients. We will include the
reversed schedule in order to assess differences in side-effects
and clinical outcome. In addition, further studies will have to
clarify the exact biological and biochemical mechanisms that
are responsible for the significant schedule-dependent
interactions.
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